Company: ATHE
Filing Date: 2025-08-29
Form Type: 20-F
Source: 0001213900-25-082027
Chunk: 80

Company: ALTERITY THERAPEUTICS LTD
Filing Date: 2025-08-29
Form: 20-F
Item: Item 6
Chunk 80
---
,000.

                                                     2025              2024     
--------------------------------------------------------------------------------
                                                   A$                A$         
Base fees                                                                       
Board – member (inclusive of Superannuation)            70,000            70,000
Board Chairman (exclusive of Superannuation)           100,000           100,000

Remuneration policy versus financial performance

The Group’s remuneration policy is not entirely based on our performance, but rather on industry practice.

The Group’s primary focus is research activities with a long-term objective of developing and commercializing our research and development results.

The tables below set out summary information about our earnings and movement in shareholder wealth for the five years to June 30, 2025:

                                                2025                      2024                      2023                      2022                      2021           
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                            A$                        A$                        A$                        A$                        A$                 
Interest income                                     446,291                   268,419                    16,436                     2,504                    20,676    
Total comprehensive loss for the year           (12,147,828   )           (19,123,464   )           (13,806,515   )           (12,847,061   )           (15,309,353   )

47

No dividends have been paid for the five years to June 30, 2025.

                                                2025                 2024                 2023                 2022                 2021         
-------------------------------------------------------------------------------------------------------------------------------------------------
                                                       A$                   A$                   A$                   A$                   A$    
ASX share price at start of the year                 0.01                 0.01                 0.01                 0.03                 0.03    
ASX share price at end of the year                   0.01                 0.01                 0.01                 0.01                 0.03    
Basic and diluted loss per share (cents)            (0.19   )            (0.52   )            (0.57   )            (0.53   )            (0.90   )

We believe that our performance in terms of earnings will remain negative while we continue in the research and/or trial phase. Shareholder wealth reflects this speculative and volatile market sector. This pattern is indicative of our performance over the past 5 years. Due to the stage of the Company, remuneration has remained consistent over this period.

Performance based rem